Podcasts about Janssen

Discover the joy of generosity and worship as we explore Philippians 4:14–20 together. When we give for God's purposes, it brings Him joy and draws us closer to His heart. We don't have to fear letting go—God promises to supply all our needs according to the riches of His glory. Be inspired to live open-handed, trusting fully in the One who provides.

Do you know that you are also God's provision to others?

Janssen, Ingo www.deutschlandfunkkultur.de, Studio 9

Today we celebrate and remember the saints that have gone before us.Sunday service times are 9 a.m., 11 a.m., and 4 p.m. at the Mission Campus in Prairie Village, Kansas, and 10 a.m. at the Antioch Campus in Overland Park, Kansas. If you are unable to attend in person, you can worship online at villagepres.org/online. Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

Recorded Live at One Heart Church (Port Lincoln) at the 9am service on the 26th of October 2025

Marc heeft auditie gedaan. Een brouwer tussen zangers, cabaretiers en andere kleinkunstenaars. Met een colbertje aan en het laptopje op schoot trok Marc de aandacht. Het contrast was groot. Als een soort oorverdovende stilte. Juan heeft vloeibaar goud meegenomen uit Spanje. Estrella Damm Bock. Een bock die geen bock had mogen heten. Uit een sixpack dat geen €18,99 had mogen kosten. In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Scripture calls us not only to believe in Christ, but to actively participate in His mission—joyfully stewarding our resources to advance the good news. As we give, serve, and stand firm in faith, may our partnership bear lasting fruit and bring glory and praise to God. Join us as we reflect on Paul's letter to the Philippians and discover what it truly means to be partners in the Gospel.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

ASHP's senior education director Cindy Von Heeringen is joined by Lisa Janssen Carlson, IDS manager, and Craig Michael, data science pharmacist, both from the University of California, San Francisco as they discuss their upcoming Midyear session that focuses on incorporating AI in current pharmacy practice settings to enhance or streamline workflows.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Jacqueline (https://jacquelinejanssen.com/) has turned all she has learned about mental illness from her son's mental health journey into incredible advocacy. Her latest book, Every Homeless Person Has a Mother, chronicles Jacqueline's experience as a parent of an adult child with schizoaffective disorder. Jacqueline's son's battle with mental illness started when he was 19 years old. Jacqueline talks about the myriad of therapies and treatments her son received and how he ultimately ended up homeless as a result of anosognosia (https://www.nami.org/about-mental-illness/common-with-mental-illness/anosognosia/) or the lack of ability to recognize and treat his mental illness. Jacqueline has been a tireless advocate for families through her own work and with NAMI (https://www.nami.org/) and encourages families to get involved in their local NAMI chapters. Jacqueline emphasizes that when a loved one is incapable of making decisions for his or her own good, HIPAA (https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html) allows mental health providers to talk to families. Jacqueline also discusses strategies for reunification of families if there is estrangement due to mental illness. Jacqueline graciously shares many resources with listeners:Family Rights and HIPAA Facts: https://drive.google.com/file/d/1W6DO-beIMgMww0xH1QTUBECiSXd85W8H/view?usp=drive_link; HIPAA Decision Tree: https://drive.google.com/file/d/1DsI-DpSCFrZLfgCknTqjaMqXTavh0AGu/view?usp=drive_link; Family Involvement Accelerates Recovery: https://drive.google.com/file/d/1IoCvWj7H56K-F4qtSL5hiGHriEn6Nk8U/view?usp=drive_link; Every Homeless Person Has A Mother: https://everyhomelesspersonhasamother.substack.com; https://www.nationalshatteringsilencecoalition.org/; What I Wish I'd Known: https://drive.google.com/file/d/1KnkPLJKF7TCNyvTwxgnZIhtAcDOCgoYQ/view?usp=drive_link

Go Ahead-watcher Sander Janssen en Sjoerd Keizer bespreken in VI ZSM het 1-1 gelijkspel van PSV in de Champions League. Vanuit Athene heeft Janssen het ook over de kansen van Go Ahead bij Panathinaikos, FC Utrecht bij SK Brann en Feyenoord thuis tegen Aston Villa.See omnystudio.com/listener for privacy information.

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Jesus is better than anyone or anything else—more worthy, more powerful, more compassionate. Because of His unmatched greatness, we are called to respond with faith, endurance, and heartfelt praise.

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE, offer a clear and practical way to work with unwholesomeness and support wholesomeness.

Note: This is the Free Content version of the interview with Tjalling Janssen. The full interview can be accessed as a Tier 2 Patreon member, or purchased for a one-time fee. More information at www.patreon.com/RejectedReligion. Tjalling is a PhD researcher at the Center for History of Hermetic Philosophy and Related Currents (HHP), based at the University of Amsterdam. His research interests include intermediary beings, magic, alchemy and Paracelsianism, and the reception of these subjects in (early to late) modernity. He investigates these topics from an environmental perspective as well as through social categories like class. His doctoral project entails an environmental reception history of the concept of elemental beings from the sixteenth to the early twentieth century, through its manifestations in magic, alchemy, literature, mining and agriculture. In this episode, we explore the shifting terrain of magical contact—where spirits, nature, and power intersect. Drawing from his article “Encounters, Evocations and Elemental Beings”, we'll trace the philosophical and esoteric implications of two very different modes of engaging with the unseen: Paracelsus's reverent encounters with elemental beings, and Dr. Rudd's ritual evocations. Along the way, we'll unpack the role of monsters, the ethics of spiritual mediation, and the deeper question of whether esotericism must rest on a singular, perennial foundation—or whether it can evolve, diversify, and apply to new contexts like ecology, psychedelics, tulpas, and even extraterrestrial contact. This is a conversation about relational knowing, cultural consciousness, and the future of interdisciplinary esoteric research.I have one correction to mention beforehand; Tjalling made a mistake in his wording when he mentioned the text De Meteoris (which comes up in the discussion), in his haste to explain the temporal trajectory. In all texts before De Meteoris elemental beings have souls. They are soulless from De Meteoris onwards, but that text lacks the possibility for elemental beings to acquire souls through marriage. The Liber de nymphis introduces that, and thus fulfills the implications of reciprocity and immanence (the “seeking out” or initiation of contact) that are absent from De Meteoris. PROGRAM NOTES Correspondences Journal Volume 12, no. 1 (2024)Encounters, Evocations and Elemental Beings Primary Source: A Book On Nymphs, Sylphs, Pygmies, and Salamanders, and On The Other Spirits (Paracelsus, Henry E. Sigerist) | PDF Secondary Sources: The Monsters of Paracelsus | Beasts, Humans, and Transhumans in the Middle Ages and the Renaissance [Abstract] Cultural History Of The Four Elements Contact Information: Tjalling D. Janssen - University of AmsterdamInstagram Theme Music and Editing: Daniel P. SheaEnd Production: Stephanie Shea

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE.

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE.

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “Phase 1 Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-like T-Cell Engager Obrixtamig in Patients with DLL3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results of Obrixtamig in patients with DLL3+ small cell lung cancer and neuroendocrine carcinomas. In this study, 168 patients were treated with Obrixtamig across four different dosing regimens. 49% of the patients had small cell lung cancer, 42% had extrapulmonary neuroendocrine carcinoma, and 8% had large cell neuroendocrine carcinoma of the lung. Patients received a median of two prior lines of therapy. 33% of the patients had brain metastases at baseline. Of note, this trial did not mandate baseline brain imaging. Maximum tolerated dose was not reached. 88% of the patients experienced a treatment-related adverse event, however, only 3.6% of the patients had to discontinue treatment due to treatment-related AEs, and dose reduction due to treatment-related AEs was documented in 2.4% of the patient population. Similar to the other DLL3-targeted bi-therapies, the most common adverse events included CRS in 57%, dysgeusia in 23%, and pyrexia in 21% of the patients. CRS events were mostly mild. They occurred more frequently in the first two to three doses. 9% of the patients experienced ICANS, of which 3% were graded as Grade 3 or higher. And let's review the efficacy results. Responses were only seen in patients who received 90 microgram per kg or more once weekly or once every three weeks dosing. The objective response rate in patients who received an effective dose was 28%. If we review by tumor type, 21% of the small cell lung cancer patients, 27% of the extrapulmonary neuroendocrine carcinoma patients, and 70% of the large cell neuroendocrine carcinoma patients had objective response. Median duration of response was 8.5 months, though this data is immature due to short follow-up. Dr. Wermke, DLL3-targeted bispecific T-cell engagers are reshaping the treatment landscape of small cell lung cancer. This trial investigates Obrixtamig in other high-grade neuroendocrine tumors as well. Can you put this trial into context for us and explain why it may represent an important step forward? Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to discuss our data today. I think the data with Obrixtamig in small cell lung cancer are largely similar to what has been observed with other bispecific T-cell engagers such as tarlatamab with respect to the response rate and duration. It has, however, been to be mentioned that BI 1438001 had a bit more liberal inclusion criteria than other trials around. You already mentioned the fact that we allowed the inclusion of patients without mandatory brain imaging, which led to some patients having their brain mets been diagnosed during the treatment with obrixtamig and then adding to the progressive disease patients. That is something which was not the case with the tarlatamab trials where you really had to have a brain imaging before, and in the Phase 1 trial you were even required to treat the brain mets before you included the patient. So it is a bit different, more poorest patient population. I think the trial adds on existing data by being the first trial to also include non-SCLC neuroendocrine carcinoma of other origin, for example from the gastrointestinal tract, and also by including large cell neuroendocrine carcinoma of the lung, which is a really hard to treat pulmonary neoplasm which currently lacks any standardized treatment. So that is really a step forward which we will build on in the future. Dr. Ece Cali: And one thing I would note in this trial, only patients with tumor expressing DLL3 were enrolled. Can you tell us a little bit more about this target, DLL3 in the context of neuroendocrine tumors, and does DLL3 expression predict clinical outcomes after treatment with DLL3 BiTEs, or do we actually need other predictive biomarkers for these novel agents? Dr. Martin Wermke: Yeah, thank you. That's a pretty interesting question. First of all, DLL3 is an atypical notch ligand, which is expressed by the majority of neuroendocrine carcinomas, virtually absent on healthy adult tissues. Therefore, turning it really into a bona fide target for T-cell engaging therapies, pretty low risk for on-target off-tumor side effects. We found that in all the patients we screened, we had an expression rate of about 94% in small cell lung cancer, 80% of large cell neuroendocrine carcinoma of the lung were positive, and also about 80% of the extrapulmonary neuroendocrine carcinoma. So it's really a high prevalence. So the fact that we only included DLL3+ tumors still means we included most of the patients that presented with these diseases. I think at the moment there are no data suggesting a clear-cut association between DLL3 expression levels and outcome on DLL3 CD3 T-cell engagers. There's also not a lot published. If you want to find this out for tarlatamab, you have to look into their patent to really see the data, but it's not clear-cut and I'm sure we need other markers to complement that. And I think what probably plays a major role is intrinsic T-cell fitness. So the question how really diseased your T-cells are, how old you are, because age also correlates with the fitness of the immune system, and other patient characteristics such as tumor burden, we've seen all across the board that the higher the tumor burden, the lower the rate of prolonged response is in such trials. And I also think we need to focus on other components of the tumor microenvironment. So see how high the T-cell infiltration with obrixtamig is and how abundant suppressive elements like regulatory T-cells or myeloid-derived suppressive cells are. That is work which is currently being done. Data are emerging, but I don't think that at the moment we have any clear biomarker helping us to select who should not receive DLL3 T-cell engagers. Dr. Ece Cali: Those are great points and there is a lot we need to learn about how to use these novel agents in the future. I'd like to highlight the results in large cell neuroendocrine carcinoma of the lung. The response rate in this group was remarkably high at 70%. Though we should note the small sample size of only 14 patients in this trial. After first line chemoimmunotherapy, current approved options for this population have very modest clinical activity. Given these trial results, how do you envision the field moving forward for patients with large cell neuroendocrine carcinoma? Dr. Martin Wermke: Yeah, I think LCNEC is really an area which urgently needs further improvement of therapeutic standards. At the moment, as I said, there is no real standard. We are usually extrapolating from results we have in small cell lung cancer or non-small cell lung cancer, but I don't think we have too many prospective trials really informing this. Of course, 14 patients is a small sample size, but I think it's still fair to say that we can claim that DLL3 T-cell engagers are not doing worse in LCNEC than they do in SCLC. And that's why I think we really need to move forward clinical trials that are specifically targeting this population. Although I fear a bit that, given the rareness of this disease and the aggressiveness of its phenotype, that this is probably not the main focus of the pharmaceutical industry. So I think it's up to us academic investigators to really come up with investigator-initiated trials trying to fill the knowledge gaps we have here. Dr. Ece Cali: And one more thing that I want to talk about is the accessibility for these drugs. These novel agents are showing real promise in improving outcomes for patients with high-grade neuroendocrine tumors, an area where progress has been limited until very recently. However, as DLL3 BiTEs become more widely used, issues of logistics and access come into sharper focus. With unique toxicities and the specialized monitoring, their use is restricted to certain centers. Looking ahead, what kinds of strategies could help mitigate some of these adverse events or make these treatments more broadly available? Dr. Martin Wermke: Yeah, I think if you look at countries like the United States where tarlatamab has already been approved, we can see how the management strategies are evolving. I've heard about a colleague equipping their patients with thermometers and a pill of Dexamethasone, alongside with a temperature control protocol and clearly instructing them, "If you measure a temperature above a certain level then start taking the Dexamethasone and come back to our office and we're going to take care of you." I think that's one way to move forward. I think we are lucky in a way that CRS usually manifests within the first 24 hours. This was the same in our study, like in the tarlatamab studies. So we really know when the time of trouble is for our patients. And in this time, I think we need to instruct the patients to stay close to the hospital. I don't think we need to hospitalize all of them, but we probably need them to stay in a nearby hotel to be able to reach the emergency room if needed in a short period of time. And I think we can also learn in this strategy how to manage bispecific antibodies from the experience our colleagues in hematology had because they have been using bispecific T-cell engagers for quite some years right now and they developed strategies and networks that were able to successfully treat these patients also on an outpatient basis. And I think that is clearly an experience we need to follow, acknowledging that we are talking about diseases which are much more frequent than the standard hematology indications. Dr. Ece Cali: Thank you so much, Dr. Wermke, for this informative discussion and for sharing your perspective on this evolving field. Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to talk about data. It was really great being able to share that, and I really think that we are just at the beginning of a new exciting area for the treatment of neuroendocrine carcinomas, and I think much improvement is yet to come for our patients. Dr. Ece Cali: Yes, that's really exciting. And thank you everyone for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Martin Wermke's Disclosures Honoraria: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer,  BMS GmbH & Co. KG, Regeneron, MJH/PER, Takeda Consulting or Advisory Role: Bristol-Myers Squib, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, immatics, Bayer, ImCheck therapeutics, AstraZeneca, Tacalyx, Regeneron, Daiichi Sankyo Europe GmbH, Zymeworks, PharmaMar, Iovance Biotherapeutics, T-Knife, Genentech Research Funding: Roche Patents, Royalties, Other Intellectual Property Travel, Accommodations, Expenses: Pfizer, Bristol-Myers Squibb, AstraZeneca,  Amgen,  GEMoaB, Sanofi/Aventis, immatics,  Merck Serono, Janssen Oncology, Iovance Biotherapeutics, Daiichi Sankyo Europe GmbH"

Become a Client: https://nomadcapitalist.com/apply/ Get our free Weekly Rundown newsletter and be the first to hear about breaking news and offers: https://nomadcapitalist.com/email Join us for the next Nomad Capitalist Live event: https://nomadcapitalist.com/live/ We are joined from the Nomad Capitalist stage by geopolitics expert Cyrus Janssen. Together with our very own Javier Carrea, he sits down for a chat on one of the most important countries in today's global landscape. The red giant, China. From how Chinese citizens define freedom differently from their Western counterparts, to the ongoing Nvidia chip saga and the Trump trade wars, they dive into everything you need to know about what might soon become the biggest economy in the world. Nomad Capitalist helps clients "go where you're treated best." We are the world's most sought-after firm for offshore tax planning, dual citizenship, international diversification, and asset protection. We use legal and ethical strategies and work exclusively with seven- and eight-figure entrepreneurs and investors. We create and execute holistic, multi-jurisdictional Plans that help clients keep more of their wealth, increase their personal freedom, and protect their families and wealth against threats in their home country. No other firm offers clients access to more potential options to relocate to, bank in, or become a citizen of. Because we do not focus only on one or a handful of countries, we can offer unbiased advice where others can't. Become Our Client: https://nomadcapitalist.com/apply/ Our Website: http://www.nomadcapitalist.com/ About Our Company: https://nomadcapitalist.com/about/ Buy Mr. Henderson's Book: https://nomadcapitalist.com/book/ Disclaimer: Neither Nomad Capitalist LTD nor its affiliates are licensed legal, financial, or tax advisors. All content published on YouTube and other platforms is intended solely for general informational and educational purposes and should not be construed as legal, tax, or financial advice. Nomad Capitalist does not offer or sell legal, financial, or tax advisory services.

Welcome to the fifth series in the annual podcast programme from Academic Archers, bringing you papers from our 2024 conference.This episode revisits the question of truth, lies and deception in Ambridge, asking whether the village is still a moral quagmire.“A Lying, Cheating, Chancer”: Truth and Deception in Ambridge - Ruth Heilbronn and Rosalind JanssenGeorge Grundy was recently branded “a lying, cheating chancer” by listeners, even compared to Boris Johnson. But research shows we all lie several times a day. Five years ago, the 2018 Academic Archers conference asked whether Ambridge was a moral quagmire. The answer was yes, with residents frequently “economical with the truth”.This paper updates that investigation. Drawing on Sisela Bok's philosophical study of lying and the history of ethical debates on truth, it distinguishes between socially beneficial lies that oil the wheels of community life and self-serving lies that erode trust.Ambridge provides ample examples: Henry lying to Helen about meeting Rob, Ardil's deception about Grey Gables' finances, Pip hiding Stella from Ruth, Helen passing off Pat's boeuf bourguignon as her own, or concealing her anorexia from Lee. Where is the line between lying, evasiveness, and omission? When does withholding truth protect others, and when does it damage relationships?The paper also considers how broader public life in 2023 reflects and refracts the moral climate in Ambridge.About the speakersDr Ruth Heilbronn is an academic whose research explores ethics, teacher education and philosophy in practice.Dr Rosalind Janssen is an independent scholar with interests in ethics and in how cultural narratives reflect moral decision-making.If you enjoy our work and would like to support Academic Archers, you can Buy Us a Coffee – buymeacoffee.com/academicarchers.

En lo último en salud y fitness edición de septiembre 2025, damos un paseo por las últimas tendencias, investigaciones y noticias en el mundo de la salud y el fitness.Imagina un tratamiento capaz de reducir el riesgo de que el cáncer regrese en casi un 30%. Un tratamiento sin los efectos secundarios devastadores de la quimio, que además te hace más fuerte, te da más energía y es completamente gratis.¿Y si te dijera que ese suplemento tan popular y caro que tienes en la despensa podría estar haciendo… bueno, prácticamente nada? ¿O que quizás estás sufriendo de más en el gimnasio para obtener los mismos resultados?En esta edición de septiembre de 2025 vamos a hablar de cómo el ejercicio podría ayudar a personas que han pasado por cáncer de colon, la verdadera efectividad del colágeno, tu café matutino y hasta el protector solar.Atajos Del Episodio02:28 - El Arma Secreta que Ya Tienes Contra el Cáncer: Tu Propio Cuerpo104:38 - Colágeno Post-Entreno: ¿El Gran Engaño del Fitness?207:30 - Entrenar al Fallo: ¿Más Sufrimiento para los Mismos Resultados?310:10 - Tu Café Matutino: ¿Estás Anulando sus Beneficios?411:57 - El Falso Dilema: Protector Solar o Vitamina D. La Ciencia Responde5Referencias:1.      Courneya, K. S., Vardy, J. L. & O'Callaghan…, C. J. Structured exercise after adjuvant chemotherapy for colon cancer. … England Journal of … (2025).2.      Aussieker, T., Kaiser, J., Hendriks, F. K. & Janssen…, T. A. H. The Effects of Ingesting a Single Bolus of Hydrolyzed Collagen versus Free Amino Acids on Muscle Connective Protein Synthesis Rates. Medicine & Science in … (2025).3.      Hermann, T., Mohan, A. E., Enes, A. & Sapuppo…, M. Without Fail: Muscular Adaptations in Single-Set Resistance Training Performed to Failure or with Repetitions-in-Reserve. Medicine & Science in … (2025).4.      Zhou, B., Ruan, M., Pan, Y., Wang, L. & Zhang, F. F. Coffee Consumption and Mortality Among US Adults: A Prospective Cohort Study. The Journal of Nutrition (2025).5.      Gatta, E. & Cappelli, C. Sunscreen and 25-hydroxyvitamin D vitamin D levels: friends or foes? Systematic review and meta-analysis. Endocrine Practice (2025).

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.

(Insight Meditation Society - Retreat Center) After an introduction to metta meditation, a guided meditation which includes the categories of benefactor, self, dear friend and a neutral being.

(Insight Meditation Society - Retreat Center) After an introduction to metta meditation, a guided meditation which includes the categories of benefactor, self, dear friend and a neutral being.

(Insight Meditation Society - Retreat Center) After an introduction to metta meditation, a guided meditation which includes the categories of benefactor, self, dear friend and a neutral being.

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

Wanna tell us how you feel about the podcast? Text us!

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

With the New Covenant in Jesus through the power of the Holy Spirit, we have forgiveness of sins and a relationship with God.

Our relationship with Jesus gives us identity, destiny, purpose, & fulfillment. It is what we all need today.

Carlos is back with the soon-to-be Mrs. Janssen herself, Alexis Bellino! The Real Housewives of OC has been nothing short of explosive these past few weeks, and we are HERE for every twist. Carlos and Alexis are getting down to the truth… the naked (wasted) truth! It’s a big, messy game of he said, she said, Katie said, Kiki said… and yes, even Slade said. Where does Katie go from here? Tune in as Carlos and Alexis break it all down.See omnystudio.com/listener for privacy information.

This week on Everybody in the Pool, we're diving into ocean intelligence. Despite covering more than 70% of the Earth, the ocean remains one of the least understood parts of our climate system — and that knowledge gap has huge consequences for weather prediction, global commerce, and climate resilience.Our guest is Tim Janssen, co-founder and CEO of Sofar Ocean, a company building the world's largest privately deployed network of ocean sensors. Their inexpensive, solar-powered Spotter buoys collect real-time data on waves, weather, and water conditions — information that fuels better climate models, safer shipping routes, and more sustainable ocean economies.We talk about:The massive “ocean data gap” and why it hinders weather and climate forecastingHow Sofar's 2,500+ Spotter buoys are creating the largest private ocean sensor networkWayfinder, Sofar's “Google Maps for ships,” and how it saves fuel and cuts emissionsWhy more ocean intelligence is critical for industries from aquaculture to shippingPartnerships with researchers, governments, and nonprofits to democratize ocean dataThe bigger vision: turning ocean information into a foundation for climate solutionsFrom global trade to Pacific Island communities, ocean intelligence has the potential to save money, reduce emissions, and protect vulnerable coastlines. Janssen explains why data may be the most important climate solution of all.LINKS:Sofar Ocean: https://www.sofarocean.com/All episodes: https://www.everybodyinthepool.com/Subscribe to the Everybody in the Pool newsletter: https://www.mollywood.co/Become a member and get an ad-free version of the podcast: https://everybodyinthepool.supercast.com/Please subscribe and tell your friends about Everybody in the Pool! Send feedback or become a sponsor: in@everybodyinthepool.com Hosted on Acast. See acast.com/privacy for more information.

Cyrus Janssen is a YouTuber, speaker and self-proclaimed US-China ambassador.  He returns to discuss his experiences and observations on the evolving relationship between China and the US, from ground level.  Today we talk about cultural exchange, economic challenges and its impact on both Chinese and American society.  We talk about the recent trend of travel vloggers and YouTubers coming to China, the rise of Chinese soft power from Wukong, Deepseek to Labubu, and its effect on American youth.  We also talk about the potential of US and China working more closely together, tariffs and societal values. _____________________ If you enjoy this show don't forget to leave a rating! Follow Us On Instagram: https://www.instagram.com/thehonestdrink_/ RedNote: THD The Honest Drink WeChat: THD_Official Find us on: Spotify, Apple, YouTube, 小红书, Ximalaya, 小宇宙, 网易云音乐, Bilibili or anywhere else you get your podcasts.

Teun Jansenn is a staff member at the European Parliament who works on issues of EU expansion and support for Ukraine. He joined Editor-in-Chief Benjamin Wittes to talk about the prospects of Europe's stepping up for Ukraine as the United States backs away. He also talked about why EU enlargement is essential to getting EU governance under control and the role that Ukraine might play in that process.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.